Generic Name:
voretigene neparvovec
Project Status:
Complete
Therapeutic Area:
Vision loss, inherited retinal dystrophy
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Luxturna
Project Line:
Reimbursement Review
Project Number:
SG0643-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the
treatment of adult and pediatric patients with vision loss due to inherited
retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have
sufficient viable retinal cells.
Submission Type:
Initial
Fee Schedule:
Schedule E
Indications:
Indicated for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.